abstract |
The present invention is directed toward inhibitors of antiplasmin cleaving enzyme for use in various therapies related to fibrin and α2-antiplasmin, and to substrates of APCE, which may be used, for example, in screening methods for identifying such inhibitors. The present invention is further directed to methods of treating or inhibiting atherosclerosis and thrombus disorders by altering the rations of types of plasma α2-antiplasmin. |